• Add this page to "Favorite pages"
  • Print the text(Open link in a new browser window)
Here begins the text.

Chief Executive’s Statement

The Pharmaceuticals and Medical Devices Agency (PMDA) puts great emphasis on communication with stakeholders, including public and industries. Since April 2020, Chief Executive Dr. FUJIWARA has been releasing various statements in English to better communicate PMDA’s positions on recent issues around global public health. Please open each file below to access individual statement. The PMDA continues to deliver information of public interest and exchange opinions with stakeholders to protect and improve the health of people by cooperating with other regulatory authorities.

Issue # Title Date
9 To Boost Japan-first Medical Product Approvals
~ PMDA Now Looks at Next Steps ~
November 24,
8 PMDA Reveals Principles on Evaluation of COVID-19 Vaccines October 12,
7 PMDA to Offer Free Scientific Advice for COVID-19 Vaccines Development October 6,
6 For Your Access to Japanese Clinical Trial/Clinical Research Information June 4,
5 First Approval of Antigen Test for COVID-19 May 13,
4 Special Approval for Emergency on Remdesivir for COVID-19 May 8,
3 Four IVDs Approvals for COVID-19 and Response to the Increased Ventilator Demand April 21,
2 PMDA Takes Further Steps to Speed up Clinical Development of COVID-19 Products April 10,
1 PMDA pledge to tackle COVID-19 Pandemic March 31,


JCN 3010005007409

Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki,
Chiyoda-ku, Tokyo 100-0013 Japan

  • Contact us
  • Access/Map

Copyright (C) Pharmaceuticals and Medical Devices Agency, All Rights Reserved.

Chief Executive’s Statement